Literature DB >> 1519481

Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy.

Y Kuroda1, K Kurohara, F Fujiyama, H Takashima, C Endo, M Matsui, R Neshige, R Kakigi.   

Abstract

Treatment with interferon-alpha (IFN-alpha) was undertaken in 16 patients with human T-lymphotropic virus type I-associated myelopathy (HAM). All patients had progressive spastic paraparesis before treatment. Twelve patients were enrolled in an open therapeutic trial with a dose of 3.0 x 10(6) IU/day of IFN-alpha and 4 in a randomized, double-blind, multidose (3.0 x 10(6), 1.0 x 10(6) or 0.3 x 10(6) IU/day) trial. IFN-alpha was injected intramuscularly for 28 days. Eight of 12 patients enrolled in an open trial and 2 patients receiving a dose of 3.0 x 10(6) IU/day of IFN-alpha in a randomized trial showed clinical improvements during and after the treatment. The results showed that, although not for all patients, systemic IFN-alpha with a dose of 3.0 x 10(6) IU/day is effective in the treatment of HAM.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1519481     DOI： 10.1111/j.1600-0404.1992.tb08059.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


  10 in total

Review 1.  Pathogenesis and treatment of HTLV-I associated myelopathy.

Authors:  G P Taylor
Journal:  Sex Transm Infect       Date:  1998-10       Impact factor: 3.519

Review 2.  Cell-Free versus Cell-to-Cell Infection by Human Immunodeficiency Virus Type 1 and Human T-Lymphotropic Virus Type 1: Exploring the Link among Viral Source, Viral Trafficking, and Viral Replication.

Authors:  Hélène Dutartre; Mathieu Clavière; Chloé Journo; Renaud Mahieux
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

3.  Alpha interferon restricts human T-lymphotropic virus type 1 and 2 de novo infection through PKR activation.

Authors:  Anne Cachat; Sébastien Alain Chevalier; Sandrine Alais; Nga Ling Ko; Lee Ratner; Chloé Journo; Hélène Dutartre; Renaud Mahieux
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

Review 4.  HTLV-1 and innate immunity.

Authors:  Chloé Journo; Renaud Mahieux
Journal:  Viruses       Date:  2011-08-08       Impact factor: 5.048

Review 5.  HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment.

Authors:  Nicolas Futsch; Renaud Mahieux; Hélène Dutartre
Journal:  Viruses       Date:  2017-12-21       Impact factor: 5.048

Review 6.  Cytokine Networks Dysregulation during HTLV-1 Infection and Associated Diseases.

Authors:  Nicolas Futsch; Gabriela Prates; Renaud Mahieux; Jorge Casseb; Hélène Dutartre
Journal:  Viruses       Date:  2018-12-05       Impact factor: 5.048

7.  Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP.

Authors:  Davi Tanajura Costa; Michael Sundberg; Lúcia Passos; André Luiz Muniz; Silvane Santos
Journal:  Case Rep Neurol Med       Date:  2012-08-16

8.  Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectives.

Authors:  Mineki Saito; Charles R M Bangham
Journal:  Leuk Res Treatment       Date:  2012-02-06

9.  Human T-lymphotropic virus 1 neurologic disease.

Authors:  Abelardo Araújo; Marco Antonio Lima; Marcus Tulius T Silva
Journal:  Curr Treat Options Neurol       Date:  2008-05       Impact factor: 3.972

10.  Interferon beta-1a treatment in HTLV-1-associated myelopathy/tropical spastic paraparesis: a case report.

Authors:  Graça Maria de Castro Viana; Marcos Antonio Custódio Neto da Silva; Victor Lima Souza; Natália Barbosa da Silva Lopes; Diego Luz Felipe da Silva; Maria do Desterro Soares Brandão Nascimento
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Sep-Oct       Impact factor: 1.846
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.